Purpose: Ewing sarcoma family tumors (ESFT) are aggressive tumors of putative stem cell origin for which prognostic biomarkers and novel treatments are needed. In several human cancers high expression of the polycomb protein BMI-1 is associated with poor outcome. We have assessed the potential clinical significance of BMI-1 expression level in ESFT.
INTRODUCTION
The Ewing sarcoma family of tumors (ESFT) are malignant neoplasms of bone and soft tissue that primarily affect children and young adults (1) . Genetically they are identified by expression of EWS-FLI1 or another related gene fusion (1) . Although their histogenesis remains elusive, recent studies suggest that ESFT may arise from malignant transformation of mesenchymal and/or neural crest stem cells (2) (3) (4) (5) (6) . Clinically they are highly aggressive malignancies with a high propensity for relapse and metastasis. Unfortunately, despite aggressive systemic cytotoxic therapy and local control measures, relapse after initial clinical remission is not uncommon and overall survival for patients with relapsed or metastatic ESFT remains less than 20% (7) . Given the profound need for novel and less toxic treatments for these patients, great hope is being placed on the development of targeted agents that will successfully inhibit biologic pathways known to contribute to ESFT growth (8) . However, knowledge about which tumors are likely to respond to these agents, such as the IGF1-R inhibitors that are currently being tested in clinical trials, is crucial if their efficacy is to be optimized. Therefore, coincident development of biomarkers that can predict response to therapy is essential.
BMI-1 is a member of the polycomb group gene family that promotes self-renewal of normal adult stem cells including neural crest stem cells through epigenetic repression of developmental and senescence pathways (reviewed in Ref (9)). In addition, BMI-1 functions as an oncogene in many human cancers and has been implicated in the self-renewal of tumor initiating cancer stem cells (10) (11) (12) . Importantly, in at least some human cancers, overexpression of the BMI-1 protein is associated with a worse clinical outcome suggesting that in these tumor types BMI-1 might be useful as a biomarker of aggressive disease (13) (14) (15) (16) (17) (18) Stained sections were assigned a BMI-1 score using published criteria (18) . In brief, the percentage of positive cells (PP) value (ranging from 0 to 3 for < 5% to > 50% positive cells, respectively) was multiplied by the signal intensity (SI) value (which ranges from 0 for absent to 3 for strongly positive) to generate a composite PPxSI value ranging from 0-9. Composite values of 0-1 are negative; 2-3 are 1+; 4-6 are 2+ and values >6 are scored as 3+.
For automated quantitative analysis (AQUA) of total and phosphorylated protein expression in tumor cells double immunofluorescence staining was performed as previously described (20) . Deparaffinized and rehydrated TMA slides were subjected to microwave epitope retrieval in 7.5 mM sodium citrate buffer, pH6 (mTOR and P-mTOR) or 1 mM EDTA buffer, pH8 (IGF1R and P-IGF1R transcript type. Survival analyses were performed using STATA software version 9.2. All reported p-values were two-sided and a p-value < 0.05 was considered significant. Database (MSigDB) and gene set enrichment analysis (GSEA) performed as described (22, 23) . In brief, the mean of the t-statistics for the transcripts of each gene set was calculated, and a p value was computed for each gene set by randomly permuting the gene labels 10,000 times. The expected false discovery rate (FDR) for multiple testing was controlled using the Benjamini and Hochberg procedure (24) . All reported p-values were two-sided.
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Statistical computations were performed using STATA software version 9.2 and R version 2.8.1 (http://www.R-project.org). 
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DISCUSSION
New therapies for ESFT are needed to both overcome resistant disease and to reduce the short-and long-term side effects associated with current cytotoxic regimens (34) . Recent preclinical data has generated great enthusiasm for biologic pathway-targeted agents, including IGF1-R antagonists (8) . In this study, we have identified a distinct subclass of ESFT that is function as an oncogene in this family of tumors. Indeed, we have found that BMI-1 promotes ESFT tumorigenicity through modulation of cell adhesion (19) . Significantly, in the current study GSEA analysis of biologic pathways identified differential up-regulation of cell adhesion molecules in BMI-1-low tumors (Table 2B) 
